Trastuzumab-induced cardiotoxicity in patients with HER-2 positive breast cancer
DOI:
https://doi.org/10.33448/rsd-v11i15.36597Keywords:
Breast neoplasm; Trastuzumab; Cardiotoxicity; Oncology.Abstract
Introdução: Trastuzumabe é um anticorpo monoclonal humanizado precursor de inibidores HER-2 positivos. A cardiotoxicidade é uma das reações adversas mais importantes do ponto de vista clínico, associada ao uso de trastuzumabe. Estudos mostram que 12,6% dos pacientes tratados com o inibidor de HER-2 apresentaram cardiotoxicidade. Objetivo: Identificar a presença de cardiotoxicidade induzida por trastuzumabe em pacientes com câncer de mama HER-2 positivo. Método: O estudo foi transversal e retrospectivo, realizado em um hospital filantrópico oncológico da cidade de Salvador, Bahia, Brasil. Os dados foram coletados por meio de prontuários eletrônicos. Foram incluídos no estudo pacientes com diagnóstico de câncer de mama HER-2 positivo, do sexo feminino, maiores de 18 anos, que utilizaram trastuzumabe no período de setembro a dezembro de 2020. As variáveis analisadas foram: idade, comorbidade, combinação de quimioterapia (monoterapia, associada) e tipo de terapia (adjuvante, neoadjuvante). Resultados: 159 pacientes foram incluídas no estudo. 10 (6%) deles apresentaram cardiotoxicidade durante o tratamento, a maioria com idade entre 40-59 anos (70%). Quanto às comorbidades, 6 (60%) pacientes eram hipertensos. 7 dos pacientes (70%) estavam em monoterapia com trastuzumabe. Todos os pacientes usaram trastuzumabe como tratamento adjuvante. Conclusão: No presente estudo, foi possível identificar a presença de cardiotoxicidade em pacientes que utilizaram trastuzumabe. Assim, é fundamental uma atenção especial ao monitoramento da função cardíaca, bem como ao acompanhamento clínico desses pacientes para identificar, precocemente, os sinais e sintomas apresentados e, assim, prevenir possíveis danos. Em pesquisas futuras, novos parâmetros de monitoramento devem ser estudados para identificar precocemente a cardiotoxicidade induzida pelo trastuzumabe.
References
Adão, R., De Keulenaer, G., Leite-Moreira, A., & Braś-Silva, C. (2013). Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention strategies. Revista Portuguesa de Cardiologia, 32(5), 395–409. https://doi.org/10.1016/J.REPC.2012.11.002
Arias, V. E. A., Gobbi, H., Ioshii, S. O., Scapulatempo, C., Da Paz, A. R., Da Silva, V. D., Uchôa, D., Zettler, C., & Soares, F. A. (2017). Assessment of HER-2 status in invasive breast cancer in Brazil. Revista Da Associacao Medica Brasileira, 63(7), 566–574. https://doi.org/10.1590/1806-9282.63.07.566
Barron, C. C., Alhussein, M. M., Kaur, U., Cosman, T. L., Tyagi, N. K., Brown, M., Mukherjee, S. D., Ellis, P. M., Dhesy-Thind, S., & Leong, D. P. (2019). An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction. Current Oncology, 26(4), 240–246. https://doi.org/10.3747/co.26.4631
Bradley, R., Braybrooke, J., Gray, R., Hills, R., Liu, Z., Peto, R., Davies, L., Dodwell, D., McGale, P., Pan, H., Taylor, C., Anderson, S., Gelber, R., Gianni, L., Jacot, W., Joensuu, H., Moreno-Aspitia, A., Piccart, M., Press, M., … Swain, S. M. (2021). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. The Lancet. Oncology, 22(8), 1139–1150. https://doi.org/10.1016/S1470-2045(21)00288-6
Buzatto, I. P. C., Ribeiro-Silva, A., Andrade, J. M., Carrara, H. H. A., Silveira, W. A., & Tiezzi, D. G. (2017). Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors. Brazilian Journal of Medical and Biological Research, 50(2). https://doi.org/10.1590/1414-431X20165674
Curigliano, G., De Azambuja, E., Lenihan, D., Calabrò, M. G., Cardinale, D., & Cipolla, C. M. (2019). Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer. The Oncologist, 24(11), e1034–e1043. https://doi.org/10.1634/THEONCOLOGIST.2018-0773
Do, M., Ferreira, C., Bhadra, D., Ii, V., Berti De Azevedo, M., & Iii, B. (2021). Incidência e mortalidade por câncer de mama e do colo do útero em um município brasileiro. https://doi.org/10.11606/s1518-8787.2021055003085
DuMond, B., Patel, V., Gross, A., Fung, A., & Weber, S. (2021). Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach. Journal of Oncology Pharmacy Practice, 27(5), 1214–1221. https://doi.org/10.1177/1078155221999712
Eiger, D., Franzoi, M. A., Pondé, N., Brandão, M., De Angelis, C., Schmitt Nogueira, M., De Hemptinne, Q., & De Azambuja, E. (2020). Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials. ESMO Open, 5(1). https://doi.org/10.1136/ESMOOPEN-2019-000659
El-Sherbeny, W. S., Sabry, N. M., & Sharbay, R. M. (2019). Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy. Journal of Echocardiography, 17(2), 76–83. https://doi.org/10.1007/S12574-018-0394-4
Esteva, F. J., Baranau, Y. V., Baryash, V., Manikhas, A., Moiseyenko, V., Dzagnidze, G., Zhavrid, E., Boliukh, D., Stroyakovskiy, D., Pikiel, J., Eniu, A. E., Li, R. K., Rusyn, A. V., Tiangco, B., Lee, S. J., Lee, S. Y., Yu, S. Y., & Stebbing, J. (2019). Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial. Cancer Chemotherapy and Pharmacology, 84(4), 839–847. https://doi.org/10.1007/s00280-019-03920-4
Florido, R., Smith, K. L., Cuomo, K. K., & Russell, S. D. (2017). Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. Journal of the American Heart Association, 6(9). https://doi.org/10.1161/JAHA.117.006915
Gabani, M., Castañeda, D., Nguyen, Q. M., Choi, S.-K., Chen, C., Mapara, A., Kassan, A., Gonzalez, A. A., Khataei, T., Ait-Aissa, K., & Kassan, M. (2021). Association of Cardiotoxicity With Doxorubicin and Trastuzumab: A Double-Edged Sword in Chemotherapy. Cureus, 13(9), e18194. https://doi.org/10.7759/CUREUS.18194
Geralda, P., De, M., Silva, P., Galdino De Paula, V., Ferreira De Almeida, L., Carvalho, E. C., Silva, S., Soares, S., Valéria, N., De, D., Souza, O., Regina, S., Pereira, M., Biancha, K., & De Andrade, S. (2021). Cardiotoxicity associated with oncological chemotherapy: Identification of risk factors. Research, Society and Development, 10(2), e9110212299–e9110212299. https://doi.org/10.33448/RSD-V10I2.12299
Koulaouzidis, G., Yung, A. E., Yung, D. E., Skonieczna-Żydecka, K., Marlicz, W., Koulaouzidis, A., & Charisopoulou, D. (2021). Conventional cardiac risk factors associated with trastuzumab-induced cardiotoxicity in breast cancer: Systematic review and meta-analysis. Current Problems in Cancer, 45(5). https://doi.org/10.1016/J.CURRPROBLCANCER.2021.100723
Mohan, N., Jiang, J., Dokmanovic, M., & Wu, W. J. (2018). Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers. Antibody Therapeutics, 1(1), 13–17. https://doi.org/10.1093/ABT/TBY003
Negishi, T., Thavendiranathan, P., Negishi, K., Marwick, T. H., Aakhus, S., Murbræch, K., Massey, R., Bansal, M., Fukuda, N., Hristova, K., Izumo, M., La Gerche, A., Costello, B., Lemieux, J., Coté, M. A., Deblois, J., Mottram, P., Miyazaki, S., Nolan, M., … Santoro, C. (2018). Rationale and Design of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes: The SUCCOUR Trial. JACC: Cardiovascular Imaging, 11(8), 1098–1105. https://doi.org/10.1016/J.JCMG.2018.03.019
Nemeth, B. T., Varga, Z. V., Wu, W. J., & Pacher, P. (2017). Trastuzumab cardiotoxicity: from clinical trials to experimental studies. British Journal of Pharmacology, 174(21), 3727–3748. https://doi.org/10.1111/BPH.13643
Oikonomou, E. K., Kokkinidis, D. G., Kampaktsis, P. N., Amir, E. A., Marwick, T. H., Gupta, D., & Thavendiranathan, P. (2019). Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis. JAMA Cardiology, 4(10), 1007–1018. https://doi.org/10.1001/JAMACARDIO.2019.2952
Pereira Vaz, J., Nogueira Da Silva, A. H., Luiz, P., Navarro, B., & Errante, P. R. (2016). Diminuição da fração de ejeção do ventrículo esquerdo (FEVE) pelo uso do Trastuzumabe em pacientes com de câncer de mama HER2 positivo. Revista de Ciências Médicas e Biológicas, 15(2), 165–171. https://doi.org/10.9771/CMBIO.V15I2.16866
Piccart, M., Procter, M., Fumagalli, D., De Azambuja, E., Clark, E., Ewer, M. S., Restuccia, E., Jerusalem, G., Dent, S., Reaby, L., Bonnefoi, H., Krop, I., Liu, T. W., kowski, T. P., Toi, M., Wilcken, N., Andersson, M., Im, Y. H., Tseng, L. M., … Thomssen, C. (2021). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years’ Follow-Up. Journal of Clinical Oncology, 39(13), 1448–1457. https://doi.org/10.1200/JCO.20.01204
Pina, L. C. de O., Axelband, F., Barbosa, M. F., & Silva, M. J. S. da. (2019). Cardiotoxicidade nas Terapias Neoadjuvante e Adjuvante do Câncer de Mama. Revista Brasileira de Cancerologia, 65(3). https://doi.org/10.32635/2176-9745.rbc.2019v65n3.404
Seferina, S. C., De Boer, M., Wouter Derksen, M., Van Den Berkmortel, F., Van Kampen, R. J. W., Agn`, A., Van De Wouw, A. J., Joore, M., Peer, P. G. M., Voogd, A. C., & Tjan-Heijnen, V. C. G. (2016). Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium. https://doi.org/10.1634/theoncologist.2015-0230
Siddiqui, M. U., Yaacoub, Y., Hanson, H. A., Junarta, J., Pasha, A. K., & Shah, M. (2022). Echocardiographic predictors of symptomatic cardiotoxicity among patients undergoing chemotherapy: A systematic review and meta-analysis. Medicine, 101(28), E29562. https://doi.org/10.1097/MD.0000000000029562
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., Pinter, T., Valero, V., Liu, M.-C., Sauter, G., von Minckwitz, G., Visco, F., Bee, V., Buyse, M., Bendahmane, B., … Crown, J. (2011). Adjuvant Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine, 365(14), 1273–1283. https://doi.org/10.1056/NEJMOA0910383
Tang, G. H., Acuna, S. A., Sevick, L., Yan, A. T., & Brezden-Masley, C. (2017). Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single “real-world” setting. Medical Oncology (Northwood, London, England), 34(9). https://doi.org/10.1007/S12032-017-1018-Y
Tsang, J. Y. S., & Tse, G. M. (2020). Molecular Classification of Breast Cancer. Advances in Anatomic Pathology, 27(1), 27–35. https://doi.org/10.1097/PAP.0000000000000232
Yang, H., Bhoo-Pathy, N., Brand, J. S., Hedayati, E., Grassmann, F., Zeng, E., Bergh, J., Bian, W., Ludvigsson, J. F., Hall, P., & Czene, K. (2022). Risk of heart disease following treatment for breast cancer - results from a population-based cohort study. ELife, 11. https://doi.org/10.7554/ELIFE.71562
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Yasmin Coutinho dos Santos ; Bruno de Almeida Ribeiro; Maria Teresita Del Nino Jesus Fernandez Bendicho; Luana Santana Bacelar; Soane da Silva Félix; Rosa Malena Fagundes Xavier
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
